ArticleNature communications2020

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.

Melanie Werner-Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.